Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Beneish M-Score: -3.07 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03613 Beijing Tong Ren Tang Chinese Medicine Co Ltd HKSE:03613
89 GF Score
Price HK$6.90
GF Value HK$9.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Beijing Tong Ren Tang Chinese Medicine Co Beneish M-Score?

Beijing Tong Ren Tang Chinese Medicine Co HKSE:03613 -1.85% 89 Beneish M-Score is -3.07 as of Jul. 19, 2026. GuruFocus rates HKSE:03613 with a GF Score™ of 89/100 and a GF Value™ of HK$9.64 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Beijing Tong Ren Tang Chinese Medicine Co ranks better than 85.29% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.07 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score or its related term are showing as below:

HKSE:03613' s Beneish M-Score Range Over the Past 10 Years
Min: -3.07   Med: -2.4   Max: -1.1
Current: -3.07

During the past 13 years, the highest Beneish M-Score of Beijing Tong Ren Tang Chinese Medicine Co was -1.10. The lowest was -3.07. And the median was -2.40.


Beijing Tong Ren Tang Chinese Medicine Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tong Ren Tang Chinese Medicine Co Beneish M-Score Chart

Beijing Tong Ren Tang Chinese Medicine Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.44 -1.93 -2.94 -1.43 -3.07

Beijing Tong Ren Tang Chinese Medicine Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.94 0.00 -1.43 0.00 -3.07

HKSE:03613 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Tong Ren Tang Chinese Medicine Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score falls into.


HKSE:03613
89GF Score
Beijing Tong Ren Tang Chinese Medicine Co Ltd HKSE:03613
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Tong Ren Tang Chinese Medicine Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Beijing Tong Ren Tang Chinese Medicine Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8454+0.528 * 1.0808+0.404 * 0.8666+0.892 * 0.939+0.115 * 0.9501
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8451+4.679 * -0.092754-0.327 * 0.9127
=-3.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was HK$418 Mil.
Revenue was HK$1,513 Mil.
Gross Profit was HK$926 Mil.
Total Current Assets was HK$4,065 Mil.
Total Assets was HK$4,661 Mil.
Property, Plant and Equipment(Net PPE) was HK$450 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$98 Mil.
Selling, General, & Admin. Expense(SGA) was HK$390 Mil.
Total Current Liabilities was HK$207 Mil.
Long-Term Debt & Capital Lease Obligation was HK$74 Mil.
Net Income was HK$397 Mil.
Gross Profit was HK$0 Mil.
Cash Flow from Operations was HK$830 Mil.
Total Receivables was HK$526 Mil.
Revenue was HK$1,612 Mil.
Gross Profit was HK$1,065 Mil.
Total Current Assets was HK$3,966 Mil.
Total Assets was HK$4,560 Mil.
Property, Plant and Equipment(Net PPE) was HK$429 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$88 Mil.
Selling, General, & Admin. Expense(SGA) was HK$492 Mil.
Total Current Liabilities was HK$235 Mil.
Long-Term Debt & Capital Lease Obligation was HK$66 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(417.55 / 1513.357) / (526.011 / 1611.644)
=0.27591 / 0.326382
=0.8454

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1065.329 / 1611.644) / (925.576 / 1513.357)
=0.66102 / 0.611605
=1.0808

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4064.756 + 449.829) / 4660.738) / (1 - (3965.747 + 428.79) / 4559.525)
=0.031358 / 0.036185
=0.8666

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1513.357 / 1611.644
=0.939

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(88.122 / (88.122 + 428.79)) / (98.364 / (98.364 + 449.829))
=0.170478 / 0.179433
=0.9501

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(390.411 / 1513.357) / (491.996 / 1611.644)
=0.257977 / 0.305276
=0.8451

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((74.242 + 206.848) / 4660.738) / ((65.941 + 235.354) / 4559.525)
=0.06031 / 0.06608
=0.9127

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(397.216 - 0 - 829.52) / 4660.738
=-0.092754

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Beijing Tong Ren Tang Chinese Medicine Co has a M-score of -3.07 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.07 mean?
Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) has a Beneish M-Score of -3.07 as of Jul. 19, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beijing Tong Ren Tang Chinese Medicine Co and its competitors. According to the industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #134 out of 911 companies in the Drug Manufacturers industry, placing it in the top 14.7%.
Is Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score too high?
Beijing Tong Ren Tang Chinese Medicine Co's current Beneish M-Score is -3.07. Based on the distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #134 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Tong Ren Tang Chinese Medicine Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tong Ren Tang Chinese Medicine Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #134 out of 911 companies for Beneish M-Score. This places Beijing Tong Ren Tang Chinese Medicine Co in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Beijing Tong Ren Tang Chinese Medicine Co and its competitors. Beijing Tong Ren Tang Chinese Medicine Co's current Beneish M-Score is -3.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tong Ren Tang Chinese Medicine Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$9.64, compared to a current price of HK$6.90 — trading 28.4% below its estimated fair value. The current Beneish M-Score is -3.07. Beijing Tong Ren Tang Chinese Medicine Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613), the current Beneish M-Score is -3.07 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tong Ren Tang Chinese Medicine Co (HKSE:03613) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co stock appears to be undervalued. The current stock price of HK$6.90 is trading 28.4% below its estimated GF Value™ of HK$9.64. GuruFocus considers Beijing Tong Ren Tang Chinese Medicine Co to be Modestly Undervalued.

Key valuation signals for HKSE:03613:

  • Beneish M-Score: -3.07
  • GF Value™: HK$9.64 vs. price of HK$6.90 (28.4% below fair value)
  • GF Score™: 89/100 with 3 warning signs

No single metric tells the full story. See the HKSE:03613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Tong Ren Tang Chinese Medicine Co Business Description

Other Exchanges TQR:Germany
Address Convention Plaza, 1 Harbour Road, Room 1405-1409, Office Tower, Wanchai, Hong Kong, HKG
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products; Chinese Mainland (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Chinese Mainland and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd; and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.
89GF Score

Get the complete analysis for HKSE:03613

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.90
Price
HK$9.64
GF Value